The general public’s concerns about patients with COVID-19 tend to focus on the respiratory effects of the virus. Thrombotic events can endanger patients during and after related hospitalization, however, indicating that urgent care providers need to be aware of and vigilant for signs that recently discharged patients could fall prey to venous thromboembolism and other events. According to an article just published by The Lancet, patients who received rivaroxaban 10 mg/day for 35 days experienced improved clinical outcomes compared with patients who received no extended thromboprophylaxis. All patients had received standard doses of heparin during their hospital stays. The Lancet article comes just weeks after JUCM published an article entitled Management of Venous Thromboembolism in Urgent Care. Read it here now.
Published on
COVID-19 Patients Fresh Out of the Hospital May Not Be Out of Danger